دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Peace of Mind: A Role in Unnecessary Care?.
Chen, Michelle M. MD, MHS 1,,; Hughes, Tasha M. MD, MPH 2; Dossett, Lesly A. MD, MPH 2,; Pitt, Susan C. MD, MPHS 3
doi : 10.1200/JCO.21.01895
Volume 40(5) pgs. 433-525 February 10, 2022
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
Krop, Ian E. MD 1,,; Im, Seock-Ah MD 2,; Barrios, Carlos MD 3,; Bonnefoi, Herve MD 4,; Gralow, Julie MD 5,; Toi, Masakazu MD 6,; Ellis, Paul A. MD 7; Gianni, Luca MD 8,; Swain, Sandra M. MD 9,; Im, Young-Hyuck MD 10; De Laurentiis, Michelino MD 11,; Nowecki, Zbigniew MD 12,; Huang, Chiun-Sheng MD 13,; Fehrenbacher, Louis MD 14; Ito, Yoshinori MD 15,; Shah, Jigna DPharm 16,; Boulet, Thomas MS 17,; Liu, Haiying MD 16,; Macharia, Harrison MSc 17,; Trask, Peter PhD 16,; Song, Chunyan MD 16,; Winer, Eric P. MD 1,; Harbeck, Nadia MD 18,
doi : 10.1200/JCO.21.00896
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
Mayer, Erica L. MD, MPH 1,,; Fesl, Christian PhD 2,; Hlauschek, Dominik MS 2,; Garcia-Estevez, Laura MD 3,4,; Burstein, Harold J. MD, PhD 1; Zdenkowski, Nicholas MD, PhD 5,; Wette, Viktor MD 6; Miller, Kathy D. MD 7,; Balic, Marija MD 8,; Mayer, Ingrid A. MD, MSCI 9,; Cameron, David MD, MSc 10,; Winer, Eric P. MD 1,; Ponce Lorenzo, Jose Juan MD 4,11,; Lake, Diana MD 12; Pristauz-Telsnigg, Gunda MD 8; Haddad, Tufia C. MD 13,; Shepherd, Lois MDCM 14; Iwata, Hiroji MD, PhD 15,; Goetz, Matthew MD 13,; Cardoso, Fatima MD 16,; Traina, Tiffany A. MD 11,; Sabanathan, Dhanusha MBBS, MMed 17; Breitenstein, Urs MD 18,; Ackerl, Kerstin MSc 2,; Metzger Filho, Otto MD 1,; Zehetner, Karin MSc 2,; Solomon, Kadine BA 19,; El-Abed, Sarra MD 20,; Theall, Kathy Puyana MD 21,; Lu, Dongrui Ray MS 22,; Dueck, Amylou PhD 23,; Gnant, Michael MD 24,; DeMichele, Angela MD, MSCE 25,
doi : 10.1200/JCO.21.01918
Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee.
Trobaugh-Lotrario, Angela MD 1; Katzenstein, Howard M. MD 2,,; Ranganathan, Sarangarajan MD 3; Lopez-Terrada, Dolores MD 4; Krailo, Mark D. PhD 5,; Piao, Jin PhD 6; Chung, Nadia MPH 6; Randazzo, Jessica BS 6; Malogolowkin, Marcio H. MD 7; Furman, Wayne L. MD 8; McCarville, Elizabeth B. MD 8; Towbin, Alexander J. MD 3,; Tiao, Greg M. MD 3; Dunn, Stephen P. MD 9; Langham, Max R. MD 8; McGahren, Eugene D. MD 10; Feusner, James MD 11; Rodriguez-Galindo, Carlos MD 8; Meyers, Rebecka L. MD 12; O'Neill, Allison F. MD 13,; Finegold, Milton J. MD 4
doi : 10.1200/JCO.21.00803
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Lyu, Ning MD 1,2,3; Wang, Xun MD 1,2,3; Li, Ji-Bin PhD 2,3,4; Lai, Jin-Fa MD 1,2,3; Chen, Qi-Feng MD 1,2,3; Li, Shao-Long MD 1,2,3; Deng, Hai-Jing PhD 2; He, Meng PhD 2; Mu, Lu-Wen MD 1; Zhao, Ming MD 1,2,3,
doi : 10.1200/JCO.21.01963
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Budde, Lihua E. MD 1,; Assouline, Sarit MD 2,; Sehn, Laurie H. MD 3,; Schuster, Stephen J. MD 4,; Yoon, Sung-Soo MD, PhD 5,; Yoon, Dok Hyun MD, PhD 6,; Matasar, Matthew J. MD 7,; Bosch, Francesc MD, PhD 8,; Kim, Won Seog MD, PhD 9; Nastoupil, Loretta J. MD 10,; Flinn, Ian W. MD, PhD 11,; Shadman, Mazyar MD, MPH 12,; Diefenbach, Catherine MD 13,; O'Hear, Carol MD, PhD 14,; Huang, Huang MSc 15,; Kwan, Antonia MBBS, PhD 14,; Lin, Chi-Chung PhD 14,; Piccione, Emily C. PhD 14,; Wei, Michael C. MD, PhD 14,; Yin, Shen PhD 14,; Barlett, Nancy L. MD 16,,
doi : 10.1200/JCO.21.00931
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
Vogelbaum, Michael A. MD, PhD 1,; Brown, Paul D. MD 2,; Messersmith, Hans MPH 3; Brastianos, Priscilla K. MD 4,; Burri, Stuart MD 5,; Cahill, Dan MD, PhD 4,; Dunn, Ian F. MD 6; Gaspar, Laurie E. MD, MBA 7,8,; Gatson, Na Tosha N. MD, PhD 9,10,; Gondi, Vinai MD 11,; Jordan, Justin T. MD 4,; Lassman, Andrew B. MD 12,; Maues, Julia MA 13,; Mohile, Nimish MD 14,; Redjal, Navid MD 15; Stevens, Glen DO, PhD 16; Sulman, Erik MD, PhD 17,; van den Bent, Martin MD 18,; Wallace, H. James MD 19; Weinberg, Jeffrey S. MD 20,; Zadeh, Gelareh MD, PhD 21; Schiff, David MD 22,
doi : 10.1200/JCO.21.02314
Prognostic Value of Circulating Tumor Cell Characteristics May Be Biased by Their Quantity.
Bos, Manouk K. MD; Kraan, Jaco PhD; Sleijfer, Stefan MD, PhD; Martens, John W. M. PhD; Beije, Nick MD, PhD
doi : 10.1200/JCO.21.01959
Reply to M. K. Bos et al.
Sperger, Jamie M. PhD; Feng, Felix Y. MD; Armstrong, Andrew J. MD; Zhao, Shuang G. MD; Lang, Joshua M. MD, MS
doi : 10.1200/JCO.21.02238
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer.
Mo, Dun-Chang MD; Ren, Tao MD
doi : 10.1200/JCO.21.02208
